Studying T Cell Responses During Anti-PD-1 Therapy in Melanoma and Lung Cancer
Monitors T cells during anti-PD-1 treatment in people with melanoma or lung cancer.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 15 Jun 2015
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- Biospecimen Collection
- Electronic Health Record Review
- Record updated
- 18 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with locally advanced or stage IV cancer, such as melanoma or lung cancer, who are about to start anti-PD-1 or anti-PD-L1 treatment. Blood samples are taken to follow T cell responses.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally or regionally advanced cancer, or stage IV cancer, confirmed by tissue examination.
- Earlier treatment
- The treating doctor must consider anti-PD-1/anti-PD-L1 therapy appropriate to start. Earlier immune checkpoint inhibitor treatment is allowed.
Main reasons for not taking part
- Cannot understand the consent form or follow the trial rules
- Receiving any other anti-cancer treatment or investigational drug at the same time (anti-PD-1/anti-PD-L1 is allowed)
- Pregnant or nursing
- Could become pregnant and unwilling to use adequate contraception
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Are 18 years of age or older
- Have histologic evidence of locally or regionally advanced or stage IV malignancy
- Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)
- Have an understanding of the protocol and its requirements, risks, and discomforts
- Are willing to undergo peripheral blood collection at the time points mentioned in the protocol
- Are able and willing to sign an informed consent
Who cannot take part
- Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
- Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeTaking people
About the trial
What the trial wants to find out
This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.
The group in the trial
- Observational (Blood and stool sample collection)
Patients undergo blood sample collection throughout the study. Patients also undergo optional stool sample collection and have their medical records reviewed on study. In addition, patients provide previously-collected tissue sample, if available.
Treatment: Biospecimen Collection and Electronic Health Record Review
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
- Plain-language title
- Studying T Cell Responses During Anti-PD-1 Therapy in Melanoma and Lung CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 June 2026